2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 3196

A Natural Language Processing System Can Capture Rheumatoid Arthritis Disease Activity Measures in US Veterans Across Multiple Sites
Abstract Number: 3197

Ultrasound Definitions for Cranial and Large Vessel Giant Cell Arteritis: Results of a Reliability Exercise on Images and Videos of the Omeract Ultrasound Large Vessel Vasculitis Task Force
Abstract Number: 3198

Inter-Reader and Intra-Reader Reliability of the New Omeract Ultrasonographic Criteria for the Diagnosis of Calcium Pyrophosphate Deposition Disease
Abstract Number: 3199

Urate Crystal Deposition and Bone Erosion in Gout: Inside-out or Outside-in? a Dual Energy Computed Tomography Study
Abstract Number: 3200

Immunoscintigraphic Detection Of Tumor Necrosis Factor By Radiolabeled Certolizumab Pegol in Patients with Erosive Hand Osteoarthritis in Relation to Disease Activity: A Proof of Concept Study
Abstract Number: 3201

Diagnostic Value of Quantitative Sialoscintigraphy Compared to Labial Salivary Gland Biopsy in Patients with Suspected SjöGren’ Syndrome
Abstract Number: 3202

Clinical and Ultrasonographic Evaluation of Joint Involvement in Patients with Systemic Sclerosis
Abstract Number: 3203

Analysis of Efficacy and Safety of Cyclophosphamide in Juvenile Dermatomyositis Using a Large National UK Cohort
Abstract Number: 3204

Body Composition and Adipose Tissue Distribution in Juvenile Dermatomyositis and Associations with Cardiac Function
Abstract Number: 3205

Efficacy and Safety of Canakinumab in Patients with Periodic Fever Syndromes (Colchicine-Resistant FMF, HIDS/MKD AND TRAPS): Results from a Phase 3, Pivotal, Umbrella Trial
Abstract Number: 3206

Effectiveness of Childhood Vaccinations in CAPS Patients Treated with Canakinumab: Results from an Open-Label Phase III Extension Study
Abstract Number: 3207

The Deficiency of Adenosine Deaminase Type 2 (DADA2)—Results of Anti-TNF Treatment in a Cohort of Patients with a History of Stroke
Abstract Number: 3208

Preliminary Response to JAK1/2 Inhibition with Baricitinib in “Candle”,“Savi” and “Candle-like” Diseases. a New Therapeutic Approach for Type I IFN Mediated Autoinflammatory Diseases
Abstract Number: 3209

Clinical and Radiological Outcomes of 5 Years Remission Steered Treatment in Early Rheumatoid and Undifferentiated Arthritis Patients
Abstract Number: 3210

10+ Years’ Follow-up of a Danish 2-Year Treat-to-Target RCT in Patients with Early Rheumatoid Arthritis: Baseline Predictors of Functional and Radiographic Outcomes

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].